INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Tax withholdingVerified data
EC

Enloe Courtney C reported BIOBIO.B

EVP, General Counsel & Sec · BIO-RAD LABORATORIES, INC. · Bio-Rad A Common Stock

Side
F
Value
$118K
Shares
305
Price
$386.11
Executed
Sep 6, 2026
Disclosed
Sep 9, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Sep 6 executedSep 9, 2026 disclosed

BIOBIO.B · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
26/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+12 / 25

    $118K reported value · 22.6% of prior position

  • Filing timing+6 / 15

    Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BIOBIO.B

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    16
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    F$173K
    487 sh
    Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    +2dSEC FORM 4

    Evidence

    17
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,044 sh
    Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    +2dSEC FORM 4

    Evidence

    9
    ES
    Evran SedatEVP, Global Supply Chain
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,044 sh
    Oct 20, 2026Oct 22, 2026
    traded Oct 20, 2026
    +2dSEC FORM 4

    Evidence

    27
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    456 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    30
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    F$90K
    233 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    27
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,370 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    30
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    F$195K
    504 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    15
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Grant or award
    A—
    4,601 sh
    Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    +5dSEC FORM 4

    Evidence

    23
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    456 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    27
    MR
    Mehta RajatEVP, GBL Commercial Operations
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,370 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    22
    EA
    Engelhardt Eva AnetteEVP, President, CDG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    F$142K
    369 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    22
    EA
    Engelhardt Eva AnetteEVP, President, CDG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    F$187K
    485 sh
    Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    +3dSEC FORM 4

    Evidence

    11
    EA
    Engelhardt Eva AnetteEVP, President, CDG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Grant or award
    A—
    4,313 sh
    Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    +5dSEC FORM 4

    Evidence

    19
    EA
    Engelhardt Eva AnetteEVP, President, CDG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,027 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    23
    EA
    Engelhardt Eva AnetteEVP, President, CDG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,152 sh
    Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    +3dSEC FORM 4

    Evidence

    23
    BJ
    Barry JamesEVP, President, LSG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,027 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    22
    BJ
    Barry JamesEVP, President, LSG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Tax withholding
    F$181K
    470 sh
    Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    +3dSEC FORM 4

    Evidence

    11
    BJ
    Barry JamesEVP, President, LSG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Grant or award
    A—
    4,313 sh
    Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    +5dSEC FORM 4

    Evidence

    23
    BJ
    Barry JamesEVP, President, LSG
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    1,056 sh
    Sep 6, 2026Sep 9, 2026
    traded Sep 6, 2026
    +3dSEC FORM 4

    Evidence

    27
    EC
    Enloe Courtney CEVP, General Counsel & Sec
    BIOBIO.BBIO-RAD LABORATORIES, INC.
    Option exercise
    M—
    685 sh
    Sep 5, 2026Sep 9, 2026
    traded Sep 5, 2026
    +4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002019843-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 6, 2026
    Published
    Sep 9, 2026
    Ingested by INSIDER
    Nov 5, 02:18 UTC
    Last re-read
    Nov 5, 02:18 UTC

    Extracted facts

    Filer
    Enloe Courtney C
    Role
    EVP, General Counsel & Sec
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    BIO-RAD LABORATORIES, INC.
    Ticker
    BIOBIO.B
    Shares
    305
    Price per share
    $386.11
    Value
    $117,764
    Execution date (reported)
    Sep 6, 2026
    Owned after transaction
    1,652 shares
    Days from execution to publication
    3

    Calculation

    Value = shares × reported price per share

    • Shares: 305
    • Price: $386.11

    = $117,764

    What this establishes

    Enloe Courtney C filed this Form 4 reporting a tax withholding of BIOBIO.B on Sep 6, 2026. It became public on Sep 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    EVP, General Counsel & Sec
    Enloe Courtney Ccik:0002019843
    Issuer
    BIO-RAD LABORATORIES, INC.cik:0000012208

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Source error

    Price history for BIOBIO.B is unavailable.

    An error occurred in the Server Components render. The specific message is omitted in production builds to avoid leaking sensitive details. A digest property is included on this error instance which may provide additional details about the nature of the error.